Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 61-year-old woman is admitted to the hospital with a 4-day history of high-grade fevers, a nonproductive cough, and right-sided pleuritic chest pain. She underwent an orthotopic liver transplant 7 months ago for primary biliary cholangitis. Her home medications include tacrolimus, mycophenolate mofetil, and low-dose prednisone. Vital signs show a temperature of 38.8°C (101.8°F), blood pressure of 118/74 mm Hg, pulse of 102/min, and respiratory rate of 20/min. Pulse oximetry is 96% on room air. Laboratory studies reveal a serum creatinine of 1.1 mg/dL and normal liver function tests. A non-contrast computed tomography scan of the chest demonstrates a 3-cm nodular opacity in the right upper lobe surrounded by a halo of ground-glass attenuation. Serum galactomannan assay is strongly positive. The medical team plans to initiate intravenous voriconazole therapy. Which of the following is the most appropriate management step regarding this patient's pharmacologic regimen?

  1. Reduce the tacrolimus dose to one-third of the current amount and closely monitor trough concentrationsAnswer
  2. B
    Increase the tacrolimus dose by 50 percent and closely monitor trough concentrations
  3. C
    Withhold mycophenolate mofetil to prevent profound azole-mediated myelosuppression
  4. D
    Maintain current immunosuppressive dosing and administer liposomal amphotericin B instead of voriconazole
  5. E
    Discontinue prednisone to prevent acute adrenal crisis secondary to azole-induced enzyme inhibition

Answer

The correct intervention is to reduce the tacrolimus dose to one-third of the current amount and closely monitor trough concentrations.
The patient has invasive pulmonary aspergillosis, for which voriconazole is the treatment of choice. Tacrolimus is a calcineurin inhibitor metabolized primarily by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system. Voriconazole is a potent inhibitor of CYP3A4. When administered concurrently, voriconazole profoundly decreases the clearance of tacrolimus, leading to a rapid and dangerous increase in serum tacrolimus concentrations. This can precipitate severe nephrotoxicity, neurotoxicity, and over-immunosuppression. To prevent this, the standard clinical intervention is to reduce the tacrolimus dose to approximately one-third of its original amount upon initiation of voriconazole, followed by frequent monitoring of tacrolimus trough levels to titrate therapy accurately.

Step-by-Step Solution

1
Identify the patient's acute infectious diagnosis.
Invasive pulmonary aspergillosis.
The patient is highly immunocompromised and presents with the classic CT finding (halo sign) and a positive serum galactomannan assay.
2
Determine the first-line pharmacologic treatment for the infection.
Intravenous voriconazole.
Voriconazole is the gold-standard initial therapy for invasive aspergillosis.
3
Evaluate for critical drug-drug interactions with the patient's baseline regimen.
Voriconazole profoundly interacts with tacrolimus.
Tacrolimus is metabolized by the hepatic CYP3A4 enzyme system, which is strongly inhibited by voriconazole.
4
Select the appropriate pharmacologic mitigation strategy.
Reduce the tacrolimus dose to one-third of its original amount.
This empirical dose reduction prevents dangerous supratherapeutic accumulation of the calcineurin inhibitor while maintaining necessary immunosuppression.

Key Concept

Pharmacokinetic dose-reduction protocols for calcineurin inhibitors when initiating potent CYP3A4 inhibitors.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic